Top Markets
#1 Akedo Akedo +111.38%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.38%
#4 Black Phoenix Black Phoenix +34.09%
#5 Velvet Velvet +33.20%
#6 Cross Cross +32.71%
#7 OVERTAKE OVERTAKE +17.22%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.83%
#9 Bitway Bitway +14.87%
#10 QANplatform QANplatform +14.54%
Coin of the day
Akedo Akedo
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Aceragen, Inc. Aceragen, Inc.

Aceragen, Inc.

ACGN
Pozycja w akcjach #39037
Aceragen, Inc., a biopharmaceutical firm in its clinical development phase,... Aceragen, Inc., a biopharmaceutical firm in its clinical development phase, operates out of Exton, Pennsylvania, and was founded in 1989. The company, which transitioned from Idera Pharmaceuticals, Inc. and adopted its current name in January 2023, concentrates on the discovery, advancement, and bringing to market of therapeutic agents for uncommon lung and autoimmune conditions exclusively within the United States. Its product development pipeline includes ACG-701, currently undergoing Phase 2 clinical evaluation for both cystic fibrosis pulmonary exacerbations and melioidosis, as well as ACG-801, which is being developed to address Farber disease. Moreover, Aceragen maintains a partnership and option agreement with Scriptr Global, Inc. This collaboration aims to pinpoint, research, and cultivate gene therapy options intended for the management, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia.
Cena akcji
$0.38
Ostatnia synchronizacja: 2023-09-01
Kapitalizacja rynkowa
$677.16K
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Aceragen, Inc. (ACGN)

Kategoria

Healthcare
Zyski dla Aceragen, Inc. (ACGN)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Aceragen, Inc., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Aceragen, Inc. od 2026 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
Za mało danych dla podanych dat.
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE